Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Akebia Therapeut Down 36.9% Since SmarTrend Downtrend Call (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on November 9th, 2017 at $15.76. In approximately 5 months, Akebia Therapeut has returned 36.87% as of today's recent price of $9.95....

AKBA : 9.24 (-0.43%)
Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Yirendai Ltd. (NYSE:YRD), Atlantic...

JAZZ : 155.64 (-1.46%)
SGH : 39.00 (-6.72%)
ACBI : 19.35 (+0.52%)
AKBA : 9.24 (-0.43%)
YRD : 36.39 (+1.17%)
SINA : 95.34 (-0.69%)
Akebia Therapeut Has Returned 38.5% Since SmarTrend Recommendation (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on November 9th, 2017 at $15.76. In approximately 5 months, Akebia Therapeut has returned 38.45% as of today's recent price of $9.70....

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Akebia Therapeut (AKBA , RDUS , FPRX , XLRN , MNTA )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

FPRX : 16.45 (+1.92%)
RDUS : 33.02 (-0.75%)
AKBA : 9.24 (-0.43%)
Akebia Therapeut Shares Down 38.2% Since SmarTrend's Sell Call (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on November 9th, 2017 at $15.76. In approximately 5 months, Akebia Therapeut has returned 38.20% as of today's recent price of $9.74....

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

MS : 53.64 (-1.51%)
AKBA : 9.24 (-0.43%)
Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

MS : 53.64 (-1.51%)
AKBA : 9.24 (-0.43%)
Akebia Therapeut Shares Down 23.6% Since SmarTrend's Sell Call (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on November 9th, 2017 at $15.76. In approximately 4 months, Akebia Therapeut has returned 23.60% as of today's recent price of $12.04....

AKBA : 9.24 (-0.43%)
Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

Stock Monitor: Akebia Therapeutics Post Earnings Reporting

CHMA : 1.50 (unch)
AKBA : 9.24 (-0.43%)
New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNB Financial Corporation (NASDAQ:CCNE),...

MESO : 5.61 (-1.41%)
OLBK : 34.49 (+0.91%)
AKBA : 9.24 (-0.43%)
CCNE : 29.35 (+1.63%)
VNET : 5.69 (-2.57%)
BSTC : 42.57 (-0.44%)
Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Akebia Therapeutics to Present at Upcoming February Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

-- Phase 3 Study of Non-Dialysis Patients in Japan Ongoing; Phase 3 Studies of Dialysis Patients to Begin in 2018 --

AKBA : 9.24 (-0.43%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 9.24 (-0.43%)
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

AKBA : 9.24 (-0.43%)
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

AERI : 54.75 (+2.05%)
AKBA : 9.24 (-0.43%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR +0.16 , HFC +0.82 , ABMD -3.27 , CAR +0.43 , URBN +0.48
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures closed the Monday session with most contracts 1 to 2 cents higher. This morning’s USDA Export Inspections report indicated corn exports at 1.719 MMT for the week of 4/19. That was a jump of 9% from the previous week and 17.18% larg...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar